Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

Studer, Urs E.; Whelan, Peter; Albrecht, Walter; Casselman, J; Reijke, Theo de; Hauri, D.; Loidl, Wolfgang; Isorna, Santiago; Sundaram, S.K.; Debois, Muriel; Collette, Laurence

doi:10.1200/jco.2005.04.7423

Cited by 313 publications

(180 citation statements)

References 15 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…This study showed an apparent advantage in treating patients immediately with androgen deprivation therapy in terms of distant progression, but mortality was significantly changed only in the subgroup with M0 (locally advanced) disease. In another study conducted by the European Organisation for Research and Treatment of Cancer (EORTC) [7], 985 men with newly diagnosed prostate cancer (T0-T4, N0-N2, M0) were randomly assigned to immediate vs delayed hormone therapy given at the time of symptomatic progression. The group that received immediate androgen deprivation showed a modest but statistically significant increase in overall survival, but no significant difference was seen in prostate cancer mortality or symptom-free survival.…”

Section: Watchful Waiting/androgen Deprivation Therapymentioning

confidence: 99%

Management of locally advanced prostate cancer

Payne¹

2008

Asian J Androl

View full text Add to dashboard Cite

The management of all stages of prostate cancer is an increasingly complex process and involves a variety of available treatments and many disciplines. Despite prostate-specific antigen (PSA) testing, the presentation of prostate cancer at a locally advanced stage is common in the UK, accounting for one-third of all new cases. There is no universally accepted definition of locally advanced prostate cancer; the term is loosely used to encompass a spectrum of disease profiles that show high-risk features. Men with high-risk prostate cancer generally have a significant risk of disease progression and cancer-related death if left untreated. High-risk patients, including those with locally advanced disease, present two specific challenges. There is a need for local control as well as a need to treat any microscopic metastases likely to be present but undetectable until disease progression. The optimal treatment approach will therefore often necessitate multiple modalities. The exact combinations, timing and intensity of treatment continue to be strongly debated. Management decisions should be made after all treatments have been discussed by a multidisciplinary team (including urologists, oncologists, radiologists, pathologists and nurse specialists) and after the balance of benefits and side effects of each therapy modality has been considered by the patient with regard to his own individual circumstances. This article reviews the current therapy options.

show abstract

Section: Watchful Waiting/androgen Deprivation Therapymentioning

confidence: 99%

Management of locally advanced prostate cancer

Payne¹

2008

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…The use of ADT alone has also been studied for high-risk disease. In a randomized trial of early versus delayed ADT alone in nonoperable patients, there was no improvement in PCSM for those receiving early ADT [28]. Thus, it appears that treatment of the primary tumor is a critical factor in improving the response of prostate cancer to ADT.…”

Section: Adjuvant Androgen Deprivationmentioning

confidence: 99%

Contemporary Management of High-risk Localized Prostate Cancer

Garzotto

Hung

2010

Curr Urol Rep

View full text Add to dashboard Cite

show abstract

“…The Medical Research Council study in locally advanced or asymptomatic metastatic PCa and the European Organisation for Research and Treatment study in newly diagnosed PCa (T0-4N0M0) illustrate that although immediate HT after diagnosis can delay disease progression in men with PCa, it does not necessarily result in an improved cancer-specific survival (CSS). 34,35 Postoperative HT in clinical settings other than PSAR The effect of adjuvant HT after RP obtained in randomized studies is presented in Table 2. Survival advantage of immediate (adjuvant) ADT after RP has only been proven in patients with positive lymph node PCa in a single randomized study.…”

Section: Adjuvant Ht After Rpmentioning

confidence: 99%

Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy

Poppel

Joniau

Cleynenbreugel

et al. 2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The aim of this review is to provide a discussion of the diagnostic evaluation of biochemical recurrence following radical prostatectomy (RP) and an overview of the postoperative hormonal treatment (HT) options. As no randomized trials in the clinical setting of postoperative prostatespecific antigen recurrence have been reported, there is no conclusive evidence that HT after RP will prolong survival or reduce morbidity. Non-traditional approaches, such as intermittent androgen deprivation, non-steroidal anti-androgens and combination of finasteride and nonsteroidal anti-androgen, are investigated and may be acceptable options. Combinations of HT with radiotherapy and/or chemotherapy for treatment of recurrent prostate cancer are under study.

show abstract

Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

Cited by 313 publications

References 15 publications

Management of locally advanced prostate cancer

Management of locally advanced prostate cancer

Contemporary Management of High-risk Localized Prostate Cancer

Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy

Contact Info

Product

Resources

About